1441 related articles for article (PubMed ID: 24522528)
1. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.
Shlush LI; Zandi S; Mitchell A; Chen WC; Brandwein JM; Gupta V; Kennedy JA; Schimmer AD; Schuh AC; Yee KW; McLeod JL; Doedens M; Medeiros JJ; Marke R; Kim HJ; Lee K; McPherson JD; Hudson TJ; ; Brown AM; Yousif F; Trinh QM; Stein LD; Minden MD; Wang JC; Dick JE
Nature; 2014 Feb; 506(7488):328-33. PubMed ID: 24522528
[TBL] [Abstract][Full Text] [Related]
2. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
Falini B; Sportoletti P; Brunetti L; Martelli MP
Br J Haematol; 2015 Aug; 170(3):305-22. PubMed ID: 25891481
[TBL] [Abstract][Full Text] [Related]
3. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
Guryanova OA; Shank K; Spitzer B; Luciani L; Koche RP; Garrett-Bakelman FE; Ganzel C; Durham BH; Mohanty A; Hoermann G; Rivera SA; Chramiec AG; Pronier E; Bastian L; Keller MD; Tovbin D; Loizou E; Weinstein AR; Gonzalez AR; Lieu YK; Rowe JM; Pastore F; McKenney AS; Krivtsov AV; Sperr WR; Cross JR; Mason CE; Tallman MS; Arcila ME; Abdel-Wahab O; Armstrong SA; Kubicek S; Staber PB; Gönen M; Paietta EM; Melnick AM; Nimer SD; Mukherjee S; Levine RL
Nat Med; 2016 Dec; 22(12):1488-1495. PubMed ID: 27841873
[TBL] [Abstract][Full Text] [Related]
4. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
5. Persistence of DNMT3A mutations at long-term remission in adult patients with AML.
Pløen GG; Nederby L; Guldberg P; Hansen M; Ebbesen LH; Jensen UB; Hokland P; Aggerholm A
Br J Haematol; 2014 Nov; 167(4):478-86. PubMed ID: 25371149
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.
Loghavi S; DiNardo CD; Furudate K; Takahashi K; Tanaka T; Short NJ; Kadia T; Konopleva M; Kanagal-Shamanna R; Farnoud NR; Pierce S; Khoury JD; Jorgensen JL; Patel KP; Daver N; Yilmaz M; Medeiros LJ; Kantarjian H; Ravandi F; Wang SA
Br J Haematol; 2021 Mar; 192(6):1054-1063. PubMed ID: 33618432
[TBL] [Abstract][Full Text] [Related]
7. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.
Wong TN; Ramsingh G; Young AL; Miller CA; Touma W; Welch JS; Lamprecht TL; Shen D; Hundal J; Fulton RS; Heath S; Baty JD; Klco JM; Ding L; Mardis ER; Westervelt P; DiPersio JF; Walter MJ; Graubert TA; Ley TJ; Druley T; Link DC; Wilson RK
Nature; 2015 Feb; 518(7540):552-555. PubMed ID: 25487151
[TBL] [Abstract][Full Text] [Related]
8. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
[TBL] [Abstract][Full Text] [Related]
9. The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.
Dunlap JB; Leonard J; Rosenberg M; Cook R; Press R; Fan G; Raess PW; Druker BJ; Traer E
Am J Hematol; 2019 Aug; 94(8):913-920. PubMed ID: 31145495
[TBL] [Abstract][Full Text] [Related]
10. Clonal hierarchy of main molecular lesions in acute myeloid leukaemia.
Herudkova Z; Culen M; Folta A; Jeziskova I; Cerna J; Loja T; Tom N; Smejkal J; Semerad L; Dvorakova D; Mayer J; Racil Z
Br J Haematol; 2020 Aug; 190(4):562-572. PubMed ID: 31822038
[TBL] [Abstract][Full Text] [Related]
11. DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation.
Koya J; Kataoka K; Sato T; Bando M; Kato Y; Tsuruta-Kishino T; Kobayashi H; Narukawa K; Miyoshi H; Shirahige K; Kurokawa M
Nat Commun; 2016 Mar; 7():10924. PubMed ID: 27010239
[TBL] [Abstract][Full Text] [Related]
12. Cell origin-dependent cooperativity of mutant Dnmt3a and Npm1 in clonal hematopoiesis and myeloid malignancy.
SanMiguel JM; Eudy E; Loberg MA; Miles LA; Stearns T; Mistry JJ; Rauh MJ; Levine RL; Trowbridge JJ
Blood Adv; 2022 Jun; 6(12):3666-3677. PubMed ID: 35413095
[TBL] [Abstract][Full Text] [Related]
13. Tracing the origins of relapse in acute myeloid leukaemia to stem cells.
Shlush LI; Mitchell A; Heisler L; Abelson S; Ng SWK; Trotman-Grant A; Medeiros JJF; Rao-Bhatia A; Jaciw-Zurakowsky I; Marke R; McLeod JL; Doedens M; Bader G; Voisin V; Xu C; McPherson JD; Hudson TJ; Wang JCY; Minden MD; Dick JE
Nature; 2017 Jul; 547(7661):104-108. PubMed ID: 28658204
[TBL] [Abstract][Full Text] [Related]
14. Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis.
Loberg MA; Bell RK; Goodwin LO; Eudy E; Miles LA; SanMiguel JM; Young K; Bergstrom DE; Levine RL; Schneider RK; Trowbridge JJ
Leukemia; 2019 Jul; 33(7):1635-1649. PubMed ID: 30692594
[TBL] [Abstract][Full Text] [Related]
15. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.
Chan SM; Majeti R
Int J Hematol; 2013 Dec; 98(6):648-57. PubMed ID: 23949914
[TBL] [Abstract][Full Text] [Related]
16. Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia.
Hirsch P; Zhang Y; Tang R; Joulin V; Boutroux H; Pronier E; Moatti H; Flandrin P; Marzac C; Bories D; Fava F; Mokrani H; Betems A; Lorre F; Favier R; Féger F; Mohty M; Douay L; Legrand O; Bilhou-Nabera C; Louache F; Delhommeau F
Nat Commun; 2016 Aug; 7():12475. PubMed ID: 27534895
[TBL] [Abstract][Full Text] [Related]
17. BET inhibitor resistance emerges from leukaemia stem cells.
Fong CY; Gilan O; Lam EY; Rubin AF; Ftouni S; Tyler D; Stanley K; Sinha D; Yeh P; Morison J; Giotopoulos G; Lugo D; Jeffrey P; Lee SC; Carpenter C; Gregory R; Ramsay RG; Lane SW; Abdel-Wahab O; Kouzarides T; Johnstone RW; Dawson SJ; Huntly BJ; Prinjha RK; Papenfuss AT; Dawson MA
Nature; 2015 Sep; 525(7570):538-42. PubMed ID: 26367796
[TBL] [Abstract][Full Text] [Related]
18. Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H-DNMT3A mutated clone of patient origin.
Martín I; Navarro B; Villamón E; Solano C; Serrano A; Calabuig M; Amat P; Domingo F; Abellán R; García F; Olivares MD; Chaves FJ; Tormo M; Hernández-Boluda JC
Exp Mol Pathol; 2018 Aug; 105(1):139-143. PubMed ID: 30017658
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
Thol F; Klesse S; Köhler L; Gabdoulline R; Kloos A; Liebich A; Wichmann M; Chaturvedi A; Fabisch J; Gaidzik VI; Paschka P; Bullinger L; Bug G; Serve H; Göhring G; Schlegelberger B; Lübbert M; Kirchner H; Wattad M; Kraemer D; Hertenstein B; Heil G; Fiedler W; Krauter J; Schlenk RF; Döhner K; Döhner H; Ganser A; Heuser M
Leukemia; 2017 Jun; 31(6):1286-1295. PubMed ID: 27881874
[TBL] [Abstract][Full Text] [Related]
20. Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response.
Scheller M; Ludwig AK; Göllner S; Rohde C; Krämer S; Stäble S; Janssen M; Müller JA; He L; Bäumer N; Arnold C; Gerß J; Schönung M; Thiede C; Niederwieser C; Niederwieser D; Serve H; Berdel WE; Thiem U; Hemmerling I; Leuschner F; Plass C; Schlesner M; Zaugg J; Milsom MD; Trumpp A; Pabst C; Lipka DB; Müller-Tidow C
Nat Cancer; 2021 May; 2(5):527-544. PubMed ID: 35122024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
